STOCK FUTURES HIT PAUSE WITH FED IN FOCUS, AMAZON EARNINGS ON DECK

Prospect of rate cuts has fallen dramatically since the start of 2024, helping drive up Treasury yields

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

1.3200

-0.0200

(-1.49%)

At close: 04:00PM EDT

1.3105

-0.01

(-0.72%)

Pre-Market:

09:28AM EDT

Trade prices are not sourced from all markets

All

Simply Wall St.
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...
PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Zacks
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.